Evotec SE

General information
Evotec SE
Essener Bogen 7
Manfred Eigen Campus
22419 Hamburg, Hamburg
Germany

Contact person: Werner Lanthaler, Chief Executive Officer
Company main phone: +49 (40) 560810
Company main fax:  +49 (40) 56081222
Website:  www.evotec.com
Year founded:1993
Source of foundation:Independent foundation
No. of employees: Worldwide:  4354
Corporate description / mission:
Evotec is a drug discovery alliance and development partnership company focused on progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. The company has existing development partnerships and product candidates both in clinical and pre-clinical development. Evotec’s iPSC platform is closely connected to a variety of in-house key technologies, defining disease signatures and causal relationships between genetic mutations and perturbation of specific molecular pathways.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1999
Remarks on ownership / listings
The company has been operating and managing its business activities under the two segments EVT Execute and EVT Innovate.
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Biosimilars
  • Cell therapy
  • Gene therapy
  • Immunotherapy
  • Small molecules
  • Stem cells
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • In-licensing
  • Manufacturer
  • Out-licensing
  • R&D
  • Service company
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Description of products:
EVT201
Eliapixant (BAY1817080)
EVT894, etc.
Technology used:
iPSC platform
Financing details
Fiscal year (end of) 2021
Revenues:EUR 618.03M
R&D expenses:EUR 72.20M
Net earnings:EUR 215.51M
No. of shares:176'952'992
Market cap. / valuation:EUR 4'924.60M
Collaborations & Clients
Partnering strategy / collaborations:
Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.


Bayer
Boehringer Ingelheim
BMS
CHDI
Galapagos
Merck
Novartis
Novo Nordisk
Pfizer
Sanofi
Takeda
UCB etc.
X